The antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention
10.3969/j.issn.1006-5725.2015.16.016
- VernacularTitle:心房颤动合并经皮冠状动脉介入治疗术后的联合抗栓治疗
- Author:
Linlin MAI
;
Yunzhao HU
;
Yanxian WU
;
Haichun OUYANG
;
Yingwen CHEN
;
Hangying WANG
- Publication Type:Journal Article
- Keywords:
Atrial fibrillation;
Coronary disease;
Angioplasty;
transluminal;
percutaneous coronary;
Warfarin;
Platelet aggregation inhibitors
- From:
The Journal of Practical Medicine
2015;31(16):2637-2640
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the efficacy and safety of singular double antithrombotie therapy (DT) using warfarin plus clopidogrel and the combined antithrombotie therapy of 3-month triple antithrombotie therapy (TT) using warfarin, aspirinand clopidogrel and 9-month double antithrombotie therapy (DT) for the patients with atrial fibrillation undergoing PCI. Methods Ninety patients with atrial fibrillation undergoing PCI were randomly divided into two groups evenly: one group was treated with dual antithrombotic therapy group (DT) and the other group with the combined therapy, e. g. 3-month triple antithrombotie therapy (TT) and 9-month double antithrombotie therapy (DT + TT for short). All patients were followed-up by 12 months. The two groups were compared in terms of incidences of death , myocardial infarction , stroke , target-vessel revascularisation , stent thrombosis and bleeding adverse events. Results The incidences of myocardial infarction, stroke, target-vessel revascularisation , stent thrombosis and bleeding adverse events in the TT + DT group were all significantly lower than the DT group (P < 0.05). The follow-up on the safety indicated that the rate of bleeding in the TT +DT group was insignificantly higher than the DT group (P > 0.05). Conclusion There is no significant difference in safety between the two groups. However, the therapy of TT + DT is more effective.
